Gilead: Cognizant extends Gilead partnership with $800 million, five-year service deal

Cognizant has announced an expansion of its relationship with biopharmaceutical company Gilead Sciences. Under the agreement, Cognizant will manage Gilead’s global IT infrastructure, platforms, applications and advanced analytics and lead initiatives designed to accelerate its digital transformation. The agreement includes renewal and expansion of Cognizant services for a total expected value of $800 million over the next five years.This collaboration is aimed at enablingGilead to streamline various parts of its business. The deal will also help the company to bring various medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer faster to the market.

Gilead has partnered with Cognizant for more than three years to adopt new technologies designed to drive better business outcomes. This includes supporting technologies that enable running business operations, new product launches and improving IT processes for efficient research, manufacturing, and commercialisation of its products.
How Cognizant will continue to support Gilead

Enhance internal and external client experience:BioPharma customers often need special and time-sensitive assistance to support their projects. With IT infrastructure, IT security and IT platform services, Cognizant expects to enable Gilead to provide a more consistent and seamless experience to over 18,000 internal users across 40+ countries globally.
Expand cloud operations: Cognizant will continue to support Gilead’s shift to cloud-computing environments as appropriate in collaboration with the hyperscalers. In addition, Cognizant will also help Gilead continue to modernise the business applications on such Cloud Platforms.

Digitally transform the business: Cognizant anticipates leveraging the power of generative AI (GenAI) and AI automation to help enhance Gilead’s customer service experience and assist it in driving greater manufacturing efficiencies. The GenAI advances should enable Gilead to provide better visibility and transparency about the company’s treatments to patients and internal employees globally. The company will leverage Cognizant’s Neuro IT service for AI automation innovation, which should help the company to bring products to market more efficiently. In addition, Cognizant will build applications and operate services that introduce new or enhanced technologies enabling efficient and differentiated business capabilities.
Data and Analytics Services: Cognizant will continue to provide support for all enterprise data and analytics platforms across all business functions, including the introduction of the latest and most relevant technologies to support differentiated business outcomes.